# A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Source: https://onco.cc/trials/nct07087158/  
OnCo record `nct07087158` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pazopanib in renal cell carcinoma, run by Imbioray (Hangzhou) Biomedicine Co., Ltd., now recruiting.

## Summary

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07087158 by Imbioray (Hangzhou) Biomedicine Co., Ltd., with 30 participants planned, started 2025-09-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: IBR854, Pazopanib. Conditions listed: Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07087158
- Phase: 2
- Setting: A Multicenter, Randomized, Open-Label, Active-Controlled Phase II Study Evaluating the Efficacy and Safety of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
- Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07087158: https://clinicaltrials.gov/study/NCT07087158

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Pazopanib](https://onco.cc/drugs/pazopanib/)

---
JSON: https://onco.cc/api/v1/entities/nct07087158.json